X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PF1801 (froniglutide) is a weekly GLP-1 receptor agonist biotherapeutic designed to increase muscle mass and strength by directly acting on muscle cells through targeting GLP-1 receptors that are overexpressed in the muscles of patients with DM/PM.
Lead Product(s): Froniglutide
Therapeutic Area: Immunology Product Name: PF1801
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2023
Details:
Under the agreement, Duke University will have the right to develop new anticancer drugs with the ELP platform technology and ImmunoForge will retain the right to develop new products in all therapeutic areas other than anticancer drugs.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Duke University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 18, 2023
Details:
Immunoforge is developing agents for rare muscle related diseases, such as Duchenne muscular dystrophy, polymyositis, and inclusion body myositis, based on its patent with PF1801 from PhaseBio, which has completed phase 2 clinical trials.
Lead Product(s): PF1801
Therapeutic Area: Genetic Disease Product Name: PF1801
Highest Development Status: Phase IProduct Type: Undisclosed
Partner/Sponsor/Collaborator: PhaseBio Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 28, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
